Vaxil Bio Ltd V.VXL

Alternate Symbol(s): VXLLF

Healthcare Biotechnology

Vaxil Bio Ltd. is a Canada-based biotechnology company. The Company is focused on a drug discovery and development platform based on Signal Peptides (SPs) which the Company deploys to fight infectious diseases and cancer. The Company’s most advanced product, ImMucin, a MUC1 SP-derived vaccine, completed a Phase I/II clinical trial in multiple myeloma. The Company also has a SP-based COVID-19 vaccine candidate and a SP-based tuberculosis vaccine / treatment candidate. In addition, The Company has mAb candidates for the treatment of oncology and infectious diseases to be used alone, and in combination with other treatments. It has also initiated a pre-clinical program for a drug delivery polymer that targets high affinity E-selectin (P-Esbp), which the Company licensed for development and commercialization from BGN Technologies. It exploits the properties of SP domains on crucial proteins to develop targeted therapies against cancer targets and infectious disease pathogens.

TSXV:VXL - Post by User

Vaxil Bio Ltd

Bullboard Posts

Comment by PowerofNowon Mar 20, 2020 9:46pm

130 Views

Post# 30832613

RE:RE:RE:Any IT guys out there? How long does it take to get a

Same on my end.

wanttoretireearly wrote: When I view the content of https://vaxil-bio.com/vaxil-immunotherapy-pipeline/ page looks as there was some error in code. The each main "drug name, coloured box" is all over the page and I can see part of the code display on page. Can't click on "drug name, coloured box" to get detail information.
Below you can see what I see displayed on screen

2[attr rowspan=”2″],ANTIGEN SPECIFIC IMMUNOTHERAPIES[attr rowspan=”2″],[attr class=”im”],FIRST VAXHIT™ GENERATED IMMUNOTHERAPY MUC1 selected as pilot target in order to demonstrate VaxHit’s ability as a platform to generate immunotherapies capable of targeting otherwise “untouchable” renowned antigens. [attr colspan=”2″; id=”cbg”], Phase-I/II complete15 myeloma patients Published BJH 2014 ORPHAN DRUG[attr colspan=”1″; class=”drk”],
Additional SP specific immune therapies in progress[attr colspan=”2″; id=”cbg”],FOLLOW-ON PRODUCTS TARGETING OTHER HIGH PROFILE CANCER ANTIGENS,[attr id=”coc”],
3[attr rowspan=”2″],SIGNAL PEPTIDE SPECIFIC ANTIBODIES[attr rowspan=”2″],[attr class=”sp2″],Novel antibodies therapeutic & diagnostic[attr id=”cbg”],First ever SP-specific antibodies & far more specific against targets, ,
[attr class=”sp6″],Novel antibodies therapeutic & diagnostic[attr id=”cbg”],First ever SP-specific antibodies & far more specific against targets,[attr id=”coc”],
4,ANTI-INFECTIVES,[attr class=”mv”],Derived from SP domains of 5 known TB vaccines[attr id=”cbg”], VaxHit™ has also led to vaccines for pathogens Superior immunity observed in large #’s,,